Shares of Insulet Co. (NASDAQ:PODD) have received a consensus recommendation of “Hold” from the nineteen brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $250.06.

Several analysts have recently commented on PODD shares. Wells Fargo & Company reaffirmed a “buy” rating on shares of Insulet in a research report on Friday, January 15th. Canaccord Genuity raised shares of Insulet from a “hold” rating to a “buy” rating and set a $280.00 price target on the stock in a research report on Thursday, March 25th. Oppenheimer lifted their price target on shares of Insulet from $235.00 to $277.00 and gave the company a “market perform” rating in a research report on Wednesday, March 3rd. SVB Leerink raised shares of Insulet from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $275.00 to $320.00 in a research report on Thursday, April 1st. Finally, BTIG Research reaffirmed a “hold” rating on shares of Insulet in a research report on Monday, February 1st.

PODD traded down $10.89 during trading on Tuesday, reaching $271.20. The company’s stock had a trading volume of 12,665 shares, compared to its average volume of 436,105. The company has a quick ratio of 5.91, a current ratio of 6.62 and a debt-to-equity ratio of 1.55. The firm has a fifty day simple moving average of $278.62 and a two-hundred day simple moving average of $264.16. Insulet has a 1 year low of $164.40 and a 1 year high of $306.46. The company has a market cap of $17.96 billion, a price-to-earnings ratio of 614.35 and a beta of 0.76.

Insulet (NASDAQ:PODD) last released its earnings results on Monday, February 22nd. The medical instruments supplier reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.22). The business had revenue of $246.10 million during the quarter, compared to analysts’ expectations of $232.89 million. Insulet had a return on equity of 8.94% and a net margin of 3.33%. The company’s revenue for the quarter was up 17.5% compared to the same quarter last year. During the same period last year, the business earned $0.08 earnings per share. As a group, equities analysts forecast that Insulet will post 0.32 EPS for the current fiscal year.

In other Insulet news, CEO Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $266.17, for a total value of $3,992,550.00. Following the completion of the transaction, the chief executive officer now owns 56,589 shares in the company, valued at $15,062,294.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.10% of the company’s stock.

Several large investors have recently bought and sold shares of PODD. ProShare Advisors LLC grew its stake in shares of Insulet by 4.2% during the fourth quarter. ProShare Advisors LLC now owns 1,184 shares of the medical instruments supplier’s stock worth $303,000 after purchasing an additional 48 shares in the last quarter. Centaurus Financial Inc. grew its stake in shares of Insulet by 6.2% during the first quarter. Centaurus Financial Inc. now owns 855 shares of the medical instruments supplier’s stock worth $223,000 after purchasing an additional 50 shares in the last quarter. Ellevest Inc. grew its stake in shares of Insulet by 39.4% during the first quarter. Ellevest Inc. now owns 216 shares of the medical instruments supplier’s stock worth $56,000 after purchasing an additional 61 shares in the last quarter. Synovus Financial Corp grew its stake in shares of Insulet by 1.8% during the fourth quarter. Synovus Financial Corp now owns 3,576 shares of the medical instruments supplier’s stock worth $925,000 after purchasing an additional 62 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in shares of Insulet by 6.6% during the fourth quarter. HighTower Advisors LLC now owns 1,220 shares of the medical instruments supplier’s stock worth $315,000 after purchasing an additional 75 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager.

Featured Article: Profit margin is different from the revenue

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.